Literature DB >> 16787406

Inhibition of 26S proteasome activity by huntingtin filaments but not inclusion bodies isolated from mouse and human brain.

Miguel Díaz-Hernández1, Adriana G Valera, María A Morán, Pilar Gómez-Ramos, Beatriz Alvarez-Castelao, José G Castaño, Félix Hernández, José J Lucas.   

Abstract

In Huntington's disease (HD), as in the rest of CAG triplet-repeat disorders, the expanded polyglutamine (polyQ)-containing proteins form intraneuronal fibrillar aggregates that are gathered into inclusion bodies (IBs). Since IBs contain ubiquitin and proteasome subunits, it was proposed that inhibition of proteasome activity might underlie pathogenesis of polyQ disorders. Recent in vitro enzymatic studies revealed the inability of eukaryotic proteasomes to digest expanded polyQ, thus suggesting that occasional failure of polyQ to exit the proteasome may interfere with its proteolytic function. However, it has also recently been found that in vitro assembled aggregates made of synthetic polyQ fail to inhibit proteasome activity. Because synthetic polyQ aggregates lack the post-translational modifications found inside affected neurons, such as poly ubiquitylation, we decided to study the effect of mutant huntingtin (htt) aggregates isolated from the Tet/HD94 mouse model and from human HD brain tissue. Here, we show that isolated ubiquitylated filamentous htt aggregates, extracted from IBs by a previously reported method, selectively inhibited the in vitro peptidase activity of the 26S but not of the 20S proteasome in a non-competitive manner. In good agreement, immuno-electron microscopy revealed a direct interaction of htt filaments with the 19S ubiquitin-interacting regulatory caps of the 26S proteasome. Here, we also report a new method for isolation of IBs based on magnetic sorting. Interestingly, isolated IBs did not modify proteasome activity. Our results therefore show that mutant htt filamentous aggregates can inhibit proteasome activity, but only when not recruited into IBs, thus strengthening the notion that IB formation is protective by neutralizing toxicity of dispersed filamentous htt aggregates.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16787406     DOI: 10.1111/j.1471-4159.2006.03968.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  38 in total

1.  Mutant huntingtin-impaired degradation of beta-catenin causes neurotoxicity in Huntington's disease.

Authors:  Juliette D Godin; Ghislaine Poizat; Miriam A Hickey; Florence Maschat; Sandrine Humbert
Journal:  EMBO J       Date:  2010-06-08       Impact factor: 11.598

2.  Sequestration of mutated alpha1-antitrypsin into inclusion bodies is a cell-protective mechanism to maintain endoplasmic reticulum function.

Authors:  Susana Granell; Giovanna Baldini; Sameer Mohammad; Vanessa Nicolin; Paola Narducci; Brian Storrie; Giulia Baldini
Journal:  Mol Biol Cell       Date:  2007-11-28       Impact factor: 4.138

Review 3.  Aggresome formation and neurodegenerative diseases: therapeutic implications.

Authors:  J A Olzmann; L Li; L S Chin
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

Review 4.  Proteostasis in Huntington's disease: disease mechanisms and therapeutic opportunities.

Authors:  Rachel J Harding; Yu-Feng Tong
Journal:  Acta Pharmacol Sin       Date:  2018-04-05       Impact factor: 6.150

Review 5.  Molecular Pathophysiology of Fragile X-Associated Tremor/Ataxia Syndrome and Perspectives for Drug Development.

Authors:  Teresa Botta-Orfila; Gian Gaetano Tartaglia; Aubin Michalon
Journal:  Cerebellum       Date:  2016-10       Impact factor: 3.847

6.  Mass spectrometric identification of novel lysine acetylation sites in huntingtin.

Authors:  Xin Cong; Jason M Held; Francesco DeGiacomo; Akilah Bonner; Jan Marie Chen; Birgit Schilling; Gregg A Czerwieniec; Bradford W Gibson; Lisa M Ellerby
Journal:  Mol Cell Proteomics       Date:  2011-06-18       Impact factor: 5.911

Review 7.  Huntington's Disease.

Authors:  Steven Finkbeiner
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-06-01       Impact factor: 10.005

8.  Epidithiodiketopiperazines Inhibit Protein Degradation by Targeting Proteasome Deubiquitinase Rpn11.

Authors:  Jing Li; Yaru Zhang; Bruno Da Silva Sil Dos Santos; Feng Wang; Yuyong Ma; Christian Perez; Yanling Yang; Junmin Peng; Seth M Cohen; Tsui-Fen Chou; Stephen T Hilton; Raymond J Deshaies
Journal:  Cell Chem Biol       Date:  2018-08-23       Impact factor: 8.116

9.  Acetylation within the First 17 Residues of Huntingtin Exon 1 Alters Aggregation and Lipid Binding.

Authors:  Maxmore Chaibva; Sudi Jawahery; Albert W Pilkington; James R Arndt; Olivia Sarver; Stephen Valentine; Silvina Matysiak; Justin Legleiter
Journal:  Biophys J       Date:  2016-07-26       Impact factor: 4.033

10.  Disruption of Rab11 activity in a knock-in mouse model of Huntington's disease.

Authors:  Xueyi Li; Ellen Sapp; Kathryn Chase; Laryssa A Comer-Tierney; Nicholas Masso; Jonathan Alexander; Patrick Reeves; Kimberly B Kegel; Antonio Valencia; Miguel Esteves; Neil Aronin; Marian Difiglia
Journal:  Neurobiol Dis       Date:  2009-08-20       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.